Overview

A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate efficacy and safety of pregabalin in the treatment of postherpetic neuralgia in a dose-ranging manner.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Pregabalin
Criteria
Inclusion Criteria:

- Visual Analogue Scale (VAS) of pain is higher than 40 mm.

- Pain is sustained for more than 3 months after healing of herpes zoster skin rash.

Exclusion Criteria:

- Malignancy within the past 2 years.

- Patients who have undergone neurolytic or neurosurgical therapy for postherpetic
neuralgia.

- Creatinine clearance and sex using the Cockcroft and Gault equation, by omitting any decimal fractions).

- Patients having other severe pain which may impair the self assessment of the pain due
to postherpetic neuralgia.

- Skin conditions in the affected dermatome that could alter sensation.